Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study

Ferlay, 2013, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, 49, 1374, 10.1016/j.ejca.2012.12.027 Davies, 2011, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 378, 771, 10.1016/S0140-6736(11)60993-8 Burstein, 2016, Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression, J Clin Oncol, 34, 1689, 10.1200/JCO.2015.65.9573 Curigliano, 2017, De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017, Ann Oncol, 28, 1700, 10.1093/annonc/mdx308 Francis, 2015, Adjuvant ovarian suppression in premenopausal breast cancer, N Engl J Med, 372, 436, 10.1056/NEJMoa1412379 Francis, 2018, Tailoring adjuvant endocrine therapy for premenopausal breast cancer, N Engl J Med, 379, 122, 10.1056/NEJMoa1803164 Pagani, 2014, Adjuvant exemestane with ovarian suppression in premenopausal breast cancer, N Engl J Med, 371, 107, 10.1056/NEJMoa1404037 R Ferreira, 2016, Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study, Breast, 29, 68, 10.1016/j.breast.2016.07.004 Lucas, 2008, Self-reported data on reproductive variables were reliable among postmenopausal women, J Clin Epidemiol, 61, 945, 10.1016/j.jclinepi.2007.11.001 Leuven Cuzick, 2007, Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials, Lancet, 369, 1711, 10.1016/S0140-6736(07)60778-8 Zhang, 2017, Effects of ovarian ablation or suppression in premenopausal breast cancer: a meta-analysis of randomized controlled trials, Eur J Surg Oncol, 43, 1161, 10.1016/j.ejso.2016.11.011 Noh, 2018, Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study, J Clin Oncol, 36, 502, 10.1200/JCO.2018.36.15_suppl.502 Qiu, 2016, Evaluating the survival benefit following ovarian function suppression in premenopausal patients with hormone receptor positive early breast cancer, Sci Rep, 6, 26627, 10.1038/srep26627 Yan, 2015, Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials, Onco Targets Ther, 8, 1433, 10.2147/OTT.S86817 Ribi, 2016, Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial, J Clin Oncol, 34, 1601, 10.1200/JCO.2015.64.8675 Tevaarwerk, 2014, Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group, J Clin Oncol, 32, 3948, 10.1200/JCO.2014.55.6993 Phillips, 2016, Adjuvant ovarian function suppression and cognitive function in women with breast cancer, Br J Cancer, 114, 956, 10.1038/bjc.2016.71 Yi, 2016, Depression and anxiety after adjuvant ovarian function suppression in premenopausal breast cancer patients, Cancer Res, 76 Regan, 2016, Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT Trials, J Clin Oncol, 34, 2221, 10.1200/JCO.2015.64.3171 Saha, 2017, Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials, J Clin Oncol, 35, 3113, 10.1200/JCO.2016.72.0946 Gnant, 2015, Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12, Ann Oncol, 26, 313, 10.1093/annonc/mdu544 Bernhard, 2015, Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials, Lancet Oncol, 16, 848, 10.1016/S1470-2045(15)00049-2 Lambertini, 2018, Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient–level data, J Clin Oncol, 36, 1981, 10.1200/JCO.2018.78.0858 Lambertini, 2019, Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application, Cancer Treat Rev, 72, 65, 10.1016/j.ctrv.2018.11.006 Regan, 2017, Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT, Ann Oncol, 28, 2225, 10.1093/annonc/mdx285 Paluch-Shimon, 2017, ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3), Breast, 35, 203, 10.1016/j.breast.2017.07.017 Oktay, 2018, Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update, J Clin Oncol, 36, 1994, 10.1200/JCO.2018.78.1914 Lambertini, 2017, Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology, Eur J Cancer, 71, 25, 10.1016/j.ejca.2016.10.034 2007, Ovarian ablation or suppression in premenopausal early breast cancer: results from the international Adjuvant Breast Cancer Ovarian Ablation or Suppression randomized trial, J Natl Cancer Inst, 99, 516, 10.1093/jnci/djk109 Baum, 2006, Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study, Eur J Cancer, 42, 895, 10.1016/j.ejca.2005.12.013 Davidson, 2005, Chemoendocrine therapy for premenopausal women with axillary lymph node–positive, steroid hormone receptor–positive breast cancer: results from INT 0101 (E5188), J Clin Oncol, 23, 5973, 10.1200/JCO.2005.05.551 Perrone, 2018, LBA14_PR The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid, Ann Oncol, 29